Completed PHASE2 INTERVENTIONAL 2-arm NCT00448409

Activity of TroVax® Alone vs. TroVax® Plus GM-CSF in Patients With Prostate Cancer

A Phase II Trial to Assess the Activity of TroVax® Alone vs. TroVax® Plus Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) in Patients With Progressive Hormone Refractory Prostate Cancer

Sponsor: Oxford BioMedica

Conditions Prostatic Neoplasms

Interventions GM-CSF TroVax

Updated 7 times since 2017 Last updated: Mar 15, 2016 Started: May 31, 2006 Primary completion: Apr 30, 2007 Completion: May 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00448409, this PHASE2 trial focuses on Prostatic Neoplasms and remains completed. Sponsored by Oxford BioMedica, it has been updated 7 times since 2006, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Oct 2021 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Oct 2021 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

May 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Oxford BioMedica
The Methodist Hospital Research Institute

Data source: The Methodist Hospital Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Houston, United States